Pathological complete remission and long-term outcome—what do we know in 2016?

The Lancet Oncology

Volumn 17, Issue 6, 2016, Pages 693-694

  Gnant, Michael ^a   Steger, Guenther G ^a   Bartsch, Rupert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TRASTUZUMAB;

BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DRUG EFFICACY; EVENT FREE SURVIVAL; HUMAN; LONG TERM CARE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; FOLLOW UP; REMISSION; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; HUMANS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84966616990     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30038-9     Document Type: Note

References (10)

1. 1 Slamon, DJ, Clark, GM, Wong, SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987), 177–182.
2. 2 Slamon, DJ, Leyland-Jones, B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001), 783–792.
3. 3 Piccart-Gebhart, M, Procter, M, Leyland-Jones, B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005), 1659–1672.
4. 4 Bear, HD, Anderson, S, Smith, RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24 (1999), 2019–2027.
5. 5 Budzar, AU, Ibrahim, NK, Francis, D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 (2005), 3676–3685.
6. 6 Swain, SM, Baselga, J, Kim, SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372 (2015), 724–734.
7. 7 Gianni, L, Pienkowski, T, Im, YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13 (2012), 25–32.
8. 8 Cortazar, P, Zhang, L, Untch, M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384 (2014), 164–172.
9. 9 Gianni, L, Pienkowski, T, Im, Y-H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016 published online May 11. http://dx.doi.org/10.1016/S1470-2045(16)00163-7.
10. 10 Hatzis, C, Symmans, WF, Zhang, Y, et al. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast cancer. Clin Cancer Res 22 (2016), 26–33.